Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1
Yoshikane Nonagase(Kindai University), Junji Tsurutani(Kindai University)
Cited by 25
Related Papers
Tobacco components stimulate Akt-dependent proliferation and NFκB-dependent survival in lung cancer cells
|Carcinogenesis|2005|289
DS‐8201a, a new HER2‐targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2‐positive gastric cancer T‐DM1 resistance
|International Journal of Cancer|2017|193